<?xml version="1.0" encoding="UTF-8"?>
<p>BDMC is the major active constituent in REVERC3. Here, we have investigated the binding position of BDMC into the active sites of cholinesterases. Initially, SWISSADME was used to predict the druggability of the molecule based on Lipinskiâ€™s rule of five. We found that BDMC satisfied the druggability criteria (
 <xref rid="table2-2050312120973499" ref-type="table">Table 2</xref>).
</p>
